Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to […]
Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from […]
The DuPont Human Microbiome Venture today announced a research partnership with The Procter & Gamble Company (P&G), focusing on the discovery and development of innovative next generation probiotics (NGPs) for human health. Over the past […]
The Pharmabiotic Research Institute (PRI), Europe’s only regulatory expertise centre for the development of microbiome-based drug products, has announced the publication of a review titled “Live biotherapeutic products: the importance of a defined regulatory framework”. […]
A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics […]
LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) […]
A research team led by the University of Oklahoma has received a $3 million National Science Foundation grant to “understand the rules of life” through microbiome research. Microbiomes, a collection of microbes in a specific […]
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a collaboration with Boehringer Ingelheim to utilize the […]
Bacterial vaginosis (BV) is an imbalance of the vaginal microbiome that can lead to adverse health outcomes, including increased likelihood of potential pathogens colonizing the vagina, yet the mechanisms underlying these processes are poorly understood. […]